• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Pipeline

Pipeline

July 19, 2021
Company Drug/Device Medical Condition Status
Artax Biopharma AX-158 T-cell-mediated diseases phase 1 trial authorized by the UK’s Medicines and Healthcare Products Regulatory Agency
iSTAR Medical MINIject primary open-angle glaucoma Investigational Device Exemption (IDE) granted by the FDA
Advaxis ADXS-504 early prostate cancer phase 1 trial initiated
ENA Respiratory INNA-051 nasal spray activation of innate immunity to virus entering through the nose phase 1 trial initiated
Synlogic Therapeutics SYNB-1934 phenylketonuria phase 1 trial initiated
Ryvu Therapeutics RVU120 acute myeloid leukemia and myelodysplastic syndrome partial clinical hold on phase 1/b trial removed by the FDA
Akeso Biopharma AK117 in combination with azacitidine acute myeloid leukemia phase 1b/2 trial authorized by the National Medical Products Administration of China
Enveric Biosciences EV101 recurrent or progressive glioblastoma phase 1/2 trial authorized by the Israeli Ministry of Health
Micron Biomedical microneedle-based measles-rubella vaccine measles and rubella phase 1/2 trial initiated in children and adults in Gambia
Sigilon SIG-001 severe or moderately severe hemophilia A phase 1/2 trial placed on clinical hold by the FDA
ImmunityBio T-Cell COVID-19 vaccine boost vaccine in people already vaccinated with a spike-only antibody-based vaccine phase 1/2/3 trial authorized by the South Africa Health Products Regulatory Authority
BriaCell Therapeutics BRIA-IMT in combination with Incyte’s retifanlimab and epacadostat advanced breast cancer phase 1/2a trial initiated
CytoDyn leronlimab metastatic triple-negative breast cancer advanced from phase 1b to phase 2 trial
Kintor Pharmaceutical pyrilutamide androgenetic alopecia phase 2 trial authorized by the FDA
Vir Biotechnology VIR-2218 with VIR-3434 chronic hepatitis B virus phase 2 trial initiated
Oryzon vafidemstat schizophrenia phase 2b trial authorized by the Spanish Drug Agency
AiCuris pritelivir acyclovir-resistant mucocutaneous herpes simplex virus (HSV) infection phase 3 trial initiated
Ortho Clinical Diagnostics VITROS anti-SARS-CoV-2 IgG quantitative test COVID-19 diagnosis Emergency Use Authorization granted by the FDA
Astellas Padcev (enfortumab vedotin-ejfv) locally advanced or metastatic urothelial cancer approved by the FDA for expanded indication
Bayer Kerendia (finerenone) patients with chronic kidney disease associated with type 2 diabetes approved by the FDA
Janssen Biotech Darzalex Faspro (daratumumab and hyaluronidase-fihj) in combination with pomalidomide and dexamethasone previously treated multiple myeloma approved by the FDA for expanded indication
Stryker InSpace balloon implant arthroscopic treatment of massive irreparable rotator cuff tears approved by the FDA
Cue Health Cue COVID-19 test COVID-19 diagnosis approved by the Central Drugs Standard Control Organization of India

 

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing